Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ W, t1 {3 e5 G. kNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, t6 r) ^ B: g1 l9 H+ Author Affiliations
0 F) C0 P# ~ a. P! j; O2 S
# l4 l4 t; @) w2 F+ ~1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * w* m1 ]" c# G' Z
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
! S. T4 W4 a p: f3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 C0 V5 ?! e. g8 @, r4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 P% r+ O8 |8 k, T `' h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ c' H. @) K) d3 l7 d6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
m M% \9 J1 z7 g( S5 O2 O: ^7Kinki University School of Medicine, Osaka 589-8511, Japan u" a. ?! E8 o/ W
8Izumi Municipal Hospital, Osaka 594-0071, Japan * k( t1 u9 @; x; u5 L+ Z% p" K3 \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
2 g6 v5 m2 N; c$ tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
) t) J# H* y+ D3 t; [AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
" B/ H; Y$ T/ `( T0 V( H! j, }! B% n1 p' ?9 W6 A
|